Literature DB >> 19435819

High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.

Dong Yin1, Seishi Ogawa, Norihiko Kawamata, Patrizia Tunici, Gaetano Finocchiaro, Marica Eoli, Christian Ruckert, Thien Huynh, Gentao Liu, Motohiro Kato, Masashi Sanada, Anna Jauch, Martin Dugas, Keith L Black, H Phillip Koeffler.   

Abstract

Glioblastoma multiforme (GBM) is an extremely malignant brain tumor. To identify new genomic alterations in GBM, genomic DNA of tumor tissue/explants from 55 individuals and 6 GBM cell lines were examined using single nucleotide polymorphism DNA microarray (SNP-Chip). Further gene expression analysis relied on an additional 56 GBM samples. SNP-Chip results were validated using several techniques, including quantitative PCR (Q-PCR), nucleotide sequencing, and a combination of Q-PCR and detection of microsatellite markers for loss of heterozygosity with normal copy number [acquired uniparental disomy (AUPD)]. Whole genomic DNA copy number in each GBM sample was profiled by SNP-Chip. Several signaling pathways were frequently abnormal. Either the p16(INK4A)/p15(INK4B)-CDK4/6-pRb or p14(ARF)-MDM2/4-p53 pathways were abnormal in 89% (49 of 55) of cases. Simultaneous abnormalities of both pathways occurred in 84% (46 of 55) samples. The phosphoinositide 3-kinase pathway was altered in 71% (39 of 55) GBMs either by deletion of PTEN or amplification of epidermal growth factor receptor and/or vascular endothelial growth factor receptor/platelet-derived growth factor receptor alpha. Deletion of chromosome 6q26-27 often occurred (16 of 55 samples). The minimum common deleted region included PARK2, PACRG, QKI, and PDE10A genes. Further reverse transcription Q-PCR studies showed that PARK2 expression was decreased in another collection of GBMs at a frequency of 61% (34 of 56) of samples. The 1p36.23 region was deleted in 35% (19 of 55) of samples. Notably, three samples had homozygous deletion encompassing this site. Also, a novel internal deletion of a putative tumor suppressor gene, LRP1B, was discovered causing an aberrant protein. AUPDs occurred in 58% (32 of 55) of the GBM samples and five of six GBM cell lines. A common AUPD was found at chromosome 17p13.3-12 (included p53 gene) in 13 of 61 samples and cell lines. Single-strand conformational polymorphism and nucleotide sequencing showed that 9 of 13 of these samples had homozygous p53 mutations, suggesting that mitotic recombination duplicated the abnormal p53 gene, probably providing a growth advantage to these cells. A significantly shortened survival time was found in patients with 13q14 (RB) deletion or 17p13.1 (p53) deletion/AUPD. Taken together, these results suggest that this technique is a rapid, robust, and inexpensive method to profile genome-wide abnormalities in GBM.

Entities:  

Mesh:

Year:  2009        PMID: 19435819     DOI: 10.1158/1541-7786.MCR-08-0270

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.

Authors:  De-Chen Lin; Liang Xu; Ye Chen; Haiyan Yan; Masaharu Hazawa; Ngan Doan; Jonathan W Said; Ling-Wen Ding; Li-Zhen Liu; Henry Yang; Shizhu Yu; Michael Kahn; Dong Yin; H Phillip Koeffler
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

3.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

Authors:  Jill M Hagenkord; Federico A Monzon; Shera F Kash; Stan Lilleberg; Qingmei Xie; Jeffrey A Kant
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

4.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

5.  Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis.

Authors:  Shuko Harada; Lindsay B Henderson; James R Eshleman; Christopher D Gocke; Peter Burger; Constance A Griffin; Denise A S Batista
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

6.  Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Authors:  Luca Morandi; Enrico Franceschi; Dario de Biase; Gianluca Marucci; Alicia Tosoni; Mario Ermani; Annalisa Pession; Giovanni Tallini; Alba Brandes
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

7.  Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.

Authors:  Musaffe Tuna; Marcel Smid; Dakai Zhu; John W M Martens; Christopher I Amos
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Authors:  Christopher G Duncan; Patrick J Killela; Cathy A Payne; Benjamin Lampson; William C Chen; Jeff Liu; David Solomon; Todd Waldman; Aaron J Towers; Simon G Gregory; Kerrie L McDonald; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Oncotarget       Date:  2010-08

Review 9.  An emerging role of PARK2 in cancer.

Authors:  Liang Xu; De-chen Lin; Dong Yin; H Phillip Koeffler
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

10.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.